{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:20:47Z","timestamp":1782980447907,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40261-018-0699-0","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T05:00:40Z","timestamp":1537074040000},"page":"1135-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout"],"prefix":"10.1007","volume":"38","author":[{"given":"Tatsuo","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-2695","authenticated-orcid":false,"given":"Tomohiko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,15]]},"reference":[{"key":"699_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30:1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"699_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald J, Khanna P, Bae S, Singh M, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431\u201346.","journal-title":"Arthritis Care Res"},{"key":"699_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"699_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"F Sivera","year":"2014","unstructured":"Sivera F, Andr\u00e9s M, Carmona L, Kydd A, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73:328\u201335.","journal-title":"Ann Rheum Dis"},{"key":"699_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1759720X16646703","volume":"8","author":"SE Sattui","year":"2016","unstructured":"Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8:145\u201359.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"699_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1291\/hypres.24.691","volume":"24","author":"K Iseki","year":"2001","unstructured":"Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691\u20137.","journal-title":"Hypertens Res."},{"key":"699_CR7","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407\u201313.","journal-title":"J Am Soc Nephrol."},{"key":"699_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","volume":"19","author":"DE Weiner","year":"2008","unstructured":"Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19:1204\u201311.","journal-title":"J Am Soc Nephrol."},{"key":"699_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51\u20139.","journal-title":"Am J Kidney Dis."},{"key":"699_CR10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rinc\u00f3n A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388\u201393.","journal-title":"Clin J Am Soc Nephrol."},{"key":"699_CR11","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1016\/j.bmcl.2009.08.091","volume":"19","author":"T Sato","year":"2009","unstructured":"Sato T, Ashizawa N, Matsumoto K, Iwanaga T, Nakamura H, Inoue T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009;19:6225\u20139.","journal-title":"Bioorg Med Chem Lett"},{"key":"699_CR12","doi-asserted-by":"publisher","first-page":"7931","DOI":"10.1073\/pnas.0400973101","volume":"101","author":"K Okamoto","year":"2004","unstructured":"Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci USA. 2004;101:7931\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"699_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1124\/jpet.110.174540","volume":"336","author":"K Matsumoto","year":"2011","unstructured":"Matsumoto K, Okamoto K, Ashizawa N, Nishino T. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011;336:95\u2013103.","journal-title":"J Pharmacol Exp Ther."},{"key":"699_CR14","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.2174\/1381612811319140010","volume":"19","author":"K Okamoto","year":"2013","unstructured":"Okamoto K, Kusano T, Nishino T. Chemical nature and reaction mechanisms of the molybdenum cofactor of xanthine oxidoreductase. Curr Pharm Des. 2013;19:2606\u201314.","journal-title":"Curr Pharm Des."},{"key":"699_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/jcpt.12392","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Sasaki T, Hashimoto H, Sakamoto R, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2016;41:298\u2013305.","journal-title":"J Clin Pharm Ther."},{"key":"699_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10067-016-3474-8","volume":"36","author":"T Hosoya","year":"2017","unstructured":"Hosoya T, Sasaki T, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clin Rheumatol. 2017;36:649\u201356.","journal-title":"Clin Rheumatol."},{"key":"699_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/jcpt.12391","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther. 2016;41:290\u20137.","journal-title":"J Clin Pharm Ther."},{"key":"699_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10157-014-0935-8","volume":"18","author":"T Hosoya","year":"2014","unstructured":"Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18:876\u201384.","journal-title":"Clin Exp Nephrol."},{"key":"699_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/jcph.226","volume":"54","author":"A Sugiyama","year":"2014","unstructured":"Sugiyama A, Hashimoto H, Nakamura Y, Fujita T, Kumagai Y. QT\/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014;54:446\u201352.","journal-title":"J Clin Pharmacol."},{"key":"699_CR20","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450\u201361.","journal-title":"N Engl J Med."},{"key":"699_CR21","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1097\/RHU.0b013e31822541d0","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol. 2011;17:S50\u20136.","journal-title":"J Clin Rheumatol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0699-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T19:18:24Z","timestamp":1568488704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0699-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0699-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,15]]},"assertion":[{"value":"15 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"TH has received consultant fees and\/or speakers\u2019 honoraria from Fuji Yakuhin Co., Ltd., the manufacturer of topiroxostat, and\/or Sanwa Kagaku Kenkyusho Co., Ltd. TI and TO are employees of Fuji Yakuhin Co., Ltd. RS and YO are employees of Sanwa Kagaku Kenkyusho Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study and its protocol were approved by the following local IRBs of participating sites: Chubu Rosai Hospital IRB (02\/22\/2010), IRB Of Kouseikai Sone Clinic (02\/24\/2010), Abe Clinic IRB (02\/24\/2010), Gifu Prefectural General Medical Center IRB (03\/17\/2010), Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital IRB (03\/18\/2010). This study was conducted in compliance with the Helsinki Declaration, Good Clinical Practice guidelines, and other relevant laws and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This study was funded by Fuji Yakuhin Co., Ltd. and Sanwa Kagaku Kenkyusho Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All patients provided written informed consent before initiation of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}